Example of Current Signal Transduction Therapy format
Recent searches

Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
Look Inside
Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format Example of Current Signal Transduction Therapy format
Sample paper formatted on SciSpace - SciSpace
This content is only for preview purposes. The original open access content can be found here.
open access Open Access

Current Signal Transduction Therapy — Template for authors

Publisher: Bentham Science
Categories Rank Trend in last 3 yrs
Pharmacology (medical) #157 of 246 up up by 43 ranks
Endocrinology #103 of 117 up up by 9 ranks
journal-quality-icon Journal quality:
Medium
calendar-icon Last 4 years overview: 72 Published Papers | 116 Citations
indexed-in-icon Indexed in: Scopus
last-updated-icon Last updated: 03/06/2020
Related journals
Insights
General info
Top papers
Popular templates
Get started guide
Why choose from SciSpace
FAQ

Related Journals

open access Open Access

Taylor and Francis

Quality:  
High
CiteRatio: 6.4
SJR: 1.187
SNIP: 1.192
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.1
SJR: 1.333
SNIP: 1.061
open access Open Access

SAGE

Quality:  
High
CiteRatio: 4.8
SJR: 1.164
SNIP: 1.22
open access Open Access

SAGE

Quality:  
High
CiteRatio: 6.3
SJR: 1.196
SNIP: 1.603

Journal Performance & Insights

CiteRatio

SCImago Journal Rank (SJR)

Source Normalized Impact per Paper (SNIP)

A measure of average citations received per peer-reviewed paper published in the journal.

Measures weighted citations received by the journal. Citation weighting depends on the categories and prestige of the citing journal.

Measures actual citations received relative to citations expected for the journal's category.

1.6

33% from 2019

CiteRatio for Current Signal Transduction Therapy from 2016 - 2020
Year Value
2020 1.6
2019 1.2
2018 0.6
2017 0.3
2016 0.9
graph view Graph view
table view Table view

0.128

10% from 2019

SJR for Current Signal Transduction Therapy from 2016 - 2020
Year Value
2020 0.128
2019 0.142
2018 0.138
2017 0.129
2016 0.232
graph view Graph view
table view Table view

0.466

121% from 2019

SNIP for Current Signal Transduction Therapy from 2016 - 2020
Year Value
2020 0.466
2019 0.211
2018 0.132
2017 0.096
2016 0.112
graph view Graph view
table view Table view

insights Insights

  • CiteRatio of this journal has increased by 33% in last years.
  • This journal’s CiteRatio is in the top 10 percentile category.

insights Insights

  • SJR of this journal has decreased by 10% in last years.
  • This journal’s SJR is in the top 10 percentile category.

insights Insights

  • SNIP of this journal has increased by 121% in last years.
  • This journal’s SNIP is in the top 10 percentile category.

Current Signal Transduction Therapy

Guideline source: View

All company, product and service names used in this website are for identification purposes only. All product names, trademarks and registered trademarks are property of their respective owners.

Use of these names, trademarks and brands does not imply endorsement or affiliation. Disclaimer Notice

Bentham Science

Current Signal Transduction Therapy

In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front li...... Read More

Pharmacology (medical)

Endocrinology

Medicine

i
Last updated on
02 Jun 2020
i
ISSN
1574-3624
i
Impact Factor
Low - 0.165
i
Open Access
No
i
Sherpa RoMEO Archiving Policy
Yellow faq
i
Plagiarism Check
Available via Turnitin
i
Endnote Style
Download Available
i
Bibliography Name
Vancouver
i
Citation Type
Numbered
[25]
i
Bibliography Example
Blonder, G E, Tinkham, M, & Klapwijk, T M. Transition from metallic to tunnel- ing regimes in superconducting microconstrictions: Excess current, charge imbalance, and supercurrent conversion. Phys. Rev. B. 2013;87(10):100510.

Top papers written in this journal

Journal Article DOI: 10.2174/157436209789057467
Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases

Topics:

Janus kinase (61%)61% related to the paper, JAK-STAT signaling pathway (59%)59% related to the paper
76 Citations
open accessOpen access Journal Article DOI: 10.2174/1574362409666140206223014
Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in Clear - Cell Renal Cell Carcinoma (ccRCC)
Zofia F. Bielecka1, Anna M. Czarnecka, Wojciech Solarek1, Anna Kornakiewicz1, Cezary Szczylik

Abstract:

Researchers have specified different subsets of tyrosine kinase inhibitors potential resistance mechanisms in clear-cell renal cell carcinoma. In most papers published until now, drug resistance is divided into intrinsic and acquired, and typically multi-drug resistance (MDR) protein is described. Herein, the authors focus on... Researchers have specified different subsets of tyrosine kinase inhibitors potential resistance mechanisms in clear-cell renal cell carcinoma. In most papers published until now, drug resistance is divided into intrinsic and acquired, and typically multi-drug resistance (MDR) protein is described. Herein, the authors focus on molecular analysis concerning acquired, non-genetic resistance to TKIs, with insight into specific biological processes. read more read less

Topics:

Clear cell renal cell carcinoma (59%)59% related to the paper, Axitinib (55%)55% related to the paper, Sunitinib (55%)55% related to the paper, Tyrosine kinase (52%)52% related to the paper, Drug resistance (52%)52% related to the paper
69 Citations
Journal Article DOI: 10.2174/157436206775269235
Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy

Abstract:

Nuclear factor-� B (NF-� B) is a transcription factor that is activated in response to various inflammatory stimuli such as cytokines, growth factors, hormones, mitogens, carcinogens, chemotherapeutic agents, viral products, eukaryotic parasites, endotoxin, fatty acids, metals, radiation, hypoxia, and psychological, physical,... Nuclear factor-� B (NF-� B) is a transcription factor that is activated in response to various inflammatory stimuli such as cytokines, growth factors, hormones, mitogens, carcinogens, chemotherapeutic agents, viral products, eukaryotic parasites, endotoxin, fatty acids, metals, radiation, hypoxia, and psychological, physical, oxidative, and chemical stresses. In addition, constitutively active NF-�B is frequently encountered in a wide variety of tumors, including breast, ovarian, colon, pancreatic, thyroid, prostate, lung, head and neck, bladder, and skin cancers; B-cell lymphoma; Hodgkin's disease; T-cell lymphoma; adult T-cell leukemia; acute lymphoblastic leukemia; multiple myeloma; chronic lymphocytic leukemia; and acute myelogenous leukemia. Furthermore, NF-�B activation has been shown to regulate the expression of over 400 genes involved in cellular transformation, proliferation, inflammation, viral replication, antiapoptosis, angiogenesis, invasion and metastasis, oxidative stress, and osteoclastogenesis. Therefore, because of the critical role NF- �B plays in the pathogenesis of cancer, specific inhibitors of this factor are being sought. Agents that prevent cancer or inflammation have been found to suppress NF-� B activation. Although IBkinase is the major kinase, over 30 different protein kinases have been linked to the activation of NF-�B by different stimuli. The development of a drug that can specifically suppress NF-�B activation requires a full understanding of the mechanism by which NF-�B is activated in response to these various stimuli. read more read less

Topics:

Cancer (58%)58% related to the paper, Chronic lymphocytic leukemia (57%)57% related to the paper, Leukemia (56%)56% related to the paper, Metastasis (54%)54% related to the paper, Kinase (52%)52% related to the paper
View PDF
67 Citations
open accessOpen access Journal Article DOI: 10.2174/1574362409666140206221931
Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops

Abstract:

The emergence of low molecular weight kinase inhibitors as “targeted” drugs has led to remarkable advances in the treatment of cancer patients. The clinical benefits of these tumor therapies, however, vary widely in patient populations and with duration of treatment. Intrinsic and acquired resistance against such drugs limits... The emergence of low molecular weight kinase inhibitors as “targeted” drugs has led to remarkable advances in the treatment of cancer patients. The clinical benefits of these tumor therapies, however, vary widely in patient populations and with duration of treatment. Intrinsic and acquired resistance against such drugs limits their efficacy. In addition to the well studied mechanisms of resistance based upon drug transport and metabolism, genetic alterations in drug target structures and the activation of compensatory cell signaling have received recent attention. Adaptive responses can be triggered which counteract the initial dependence of tumor cells upon a particular signaling molecule and allow only a transient inhibition of tumor cell growth. These compensating signaling mechanisms are often based upon the relief of repression of regulatory feedback loops. They might involve cell autonomous, intracellular events or they can be mediated via the secretion of growth factor receptor ligands into the tumor microenvironment and signal induction in an auto- or paracrine fashion. The transcription factors Stat3 and Stat5 mediate the biological functions of cytokines, interleukins and growth factors and can be considered as endpoints of multiple signaling pathways. In normal cells this activation is transient and the Stat molecules return to their non-phosphorylated state within a short time period. In tumor cells the balance between activating and de-activating signals is disturbed resulting in the persistent activation of Stat3 or Stat5. The constant activation of Stat3 induces the expression of target genes, which cause the proliferation and survival of cancer cells, as well as their migration and invasive behavior. Activating components of the Jak-Stat pathway have been recognized as potentially valuable drug targets and important principles of compensatory signaling circuit induction during targeted drug treatment have been discovered in the context of kinase inhibition studies in HNSCC cells [1]. The treatment of HNSCC with a specific inhibitor of c-Src, initially resulted in reduced Stat3 and Stat5 activation and subsequently an arrest of cell proliferation and increased apoptosis. However, the inhibition of c-Src only caused a persistent inhibition of Stat5, whereas the inhibition of Stat3 was only transient. The activation of Stat3 was restored within a short time period in the presence of the c-Src inhibitor. This process is mediated through the suppression of P-Stat5 activity and the decrease in the expression of the Stat5 dependent target gene SOCS2, a negative regulator of Jak2. Jak2 activity is enhanced upon SOCS2 downregulation and causes the reactivation of Stat3. A similar observation has been made upon inhibition of Bmx, bone marrow kinase x-linked, activated in the murine glioma cell lines Tu-2449 and Tu-9648. Its inhibition resulted in a transient decrease of P-Stat3 and the induction of a compensatory Stat3 activation mechanism, possibly through the relief of negative feedback inhibition and Jak2 activation. These observations indicate that the inhibition of a single tyrosine kinase might not be sufficient to induce lasting therapeutic effects in cancer patients. Compensatory kinases and pathways might become activated and maintain the growth and survival of tumor cells. The definition of these escape pathways and their preemptive inhibition will suggest effective new combination therapies for cancer. read more read less

Topics:

Growth factor receptor (57%)57% related to the paper, Signal Induction (56%)56% related to the paper, Cell signaling (56%)56% related to the paper, Tumor microenvironment (56%)56% related to the paper, Signal transduction (56%)56% related to the paper
66 Citations
open accessOpen access Journal Article DOI: 10.2174/157436210790226537
Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes
Tracey M. Gloster1, David J. Vocadlo1

Abstract:

The post-translational modification of nucleocytoplasmic proteins with O-linked 2-acetamido-2-deoxy-d-glucopyranose (O-GlcNAc) is a topic of considerable interest and attracts a great deal of research effort. O-GlcNAcylation is a dynamic process which can occur multiple times over the lifetime of a protein, sometimes in a rec... The post-translational modification of nucleocytoplasmic proteins with O-linked 2-acetamido-2-deoxy-d-glucopyranose (O-GlcNAc) is a topic of considerable interest and attracts a great deal of research effort. O-GlcNAcylation is a dynamic process which can occur multiple times over the lifetime of a protein, sometimes in a reciprocal relationship with phosphorylation. Several hundred proteins, which are involved in a diverse range of cellular processes, have been identified as being modified with the monosaccharide. The control of the O-GlcNAc modification state on different protein targets appears to be important in the aetiology of a number of diseases, including type II diabetes, neurodegenerative diseases and cancer. Two enzymes are responsible for the addition and removal of the O-GlcNAc modification: uridine diphospho-N-acetylglucosamine:polypeptide beta-N-acetylglucosaminyltransferase (OGT) and O-GlcNAcase (OGA), respectively. Over the past decade the volume of information known about these two enzymes has increased significantly. In particular, mechanistic studies of OGA, in conjunction with structural studies of bacterial homologues of OGA have stimulated the design of inhibitors and offered a rationale for the binding of certain potent and selective inhibitors. Mechanistic information about OGT lags a little way behind OGA, but the recent deduction of the structure of an OGT bacterial homologue should now drive these studies forward. read more read less
65 Citations
Author Pic

SciSpace is a very innovative solution to the formatting problem and existing providers, such as Mendeley or Word did not really evolve in recent years.

- Andreas Frutiger, Researcher, ETH Zurich, Institute for Biomedical Engineering

Get MS-Word and LaTeX output to any Journal within seconds
1
Choose a template
Select a template from a library of 40,000+ templates
2
Import a MS-Word file or start fresh
It takes only few seconds to import
3
View and edit your final output
SciSpace will automatically format your output to meet journal guidelines
4
Submit directly or Download
Submit to journal directly or Download in PDF, MS Word or LaTeX

(Before submission check for plagiarism via Turnitin)

clock Less than 3 minutes

What to expect from SciSpace?

Speed and accuracy over MS Word

''

With SciSpace, you do not need a word template for Current Signal Transduction Therapy.

It automatically formats your research paper to Bentham Science formatting guidelines and citation style.

You can download a submission ready research paper in pdf, LaTeX and docx formats.

Time comparison

Time taken to format a paper and Compliance with guidelines

Plagiarism Reports via Turnitin

SciSpace has partnered with Turnitin, the leading provider of Plagiarism Check software.

Using this service, researchers can compare submissions against more than 170 million scholarly articles, a database of 70+ billion current and archived web pages. How Turnitin Integration works?

Turnitin Stats
Publisher Logos

Freedom from formatting guidelines

One editor, 100K journal formats – world's largest collection of journal templates

With such a huge verified library, what you need is already there.

publisher-logos

Easy support from all your favorite tools

Current Signal Transduction Therapy format uses Vancouver citation style.

Automatically format and order your citations and bibliography in a click.

SciSpace allows imports from all reference managers like Mendeley, Zotero, Endnote, Google Scholar etc.

Frequently asked questions

1. Can I write Current Signal Transduction Therapy in LaTeX?

Absolutely not! Our tool has been designed to help you focus on writing. You can write your entire paper as per the Current Signal Transduction Therapy guidelines and auto format it.

2. Do you follow the Current Signal Transduction Therapy guidelines?

Yes, the template is compliant with the Current Signal Transduction Therapy guidelines. Our experts at SciSpace ensure that. If there are any changes to the journal's guidelines, we'll change our algorithm accordingly.

3. Can I cite my article in multiple styles in Current Signal Transduction Therapy?

Of course! We support all the top citation styles, such as APA style, MLA style, Vancouver style, Harvard style, and Chicago style. For example, when you write your paper and hit autoformat, our system will automatically update your article as per the Current Signal Transduction Therapy citation style.

4. Can I use the Current Signal Transduction Therapy templates for free?

Sign up for our free trial, and you'll be able to use all our features for seven days. You'll see how helpful they are and how inexpensive they are compared to other options, Especially for Current Signal Transduction Therapy.

5. Can I use a manuscript in Current Signal Transduction Therapy that I have written in MS Word?

Yes. You can choose the right template, copy-paste the contents from the word document, and click on auto-format. Once you're done, you'll have a publish-ready paper Current Signal Transduction Therapy that you can download at the end.

6. How long does it usually take you to format my papers in Current Signal Transduction Therapy?

It only takes a matter of seconds to edit your manuscript. Besides that, our intuitive editor saves you from writing and formatting it in Current Signal Transduction Therapy.

7. Where can I find the template for the Current Signal Transduction Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Signal Transduction Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

8. Can I reformat my paper to fit the Current Signal Transduction Therapy's guidelines?

Of course! You can do this using our intuitive editor. It's very easy. If you need help, our support team is always ready to assist you.

9. Current Signal Transduction Therapy an online tool or is there a desktop version?

SciSpace's Current Signal Transduction Therapy is currently available as an online tool. We're developing a desktop version, too. You can request (or upvote) any features that you think would be helpful for you and other researchers in the "feature request" section of your account once you've signed up with us.

10. I cannot find my template in your gallery. Can you create it for me like Current Signal Transduction Therapy?

Sure. You can request any template and we'll have it setup within a few days. You can find the request box in Journal Gallery on the right side bar under the heading, "Couldn't find the format you were looking for like Current Signal Transduction Therapy?”

11. What is the output that I would get after using Current Signal Transduction Therapy?

After writing your paper autoformatting in Current Signal Transduction Therapy, you can download it in multiple formats, viz., PDF, Docx, and LaTeX.

12. Is Current Signal Transduction Therapy's impact factor high enough that I should try publishing my article there?

To be honest, the answer is no. The impact factor is one of the many elements that determine the quality of a journal. Few of these factors include review board, rejection rates, frequency of inclusion in indexes, and Eigenfactor. You need to assess all these factors before you make your final call.

13. What is Sherpa RoMEO Archiving Policy for Current Signal Transduction Therapy?

SHERPA/RoMEO Database

We extracted this data from Sherpa Romeo to help researchers understand the access level of this journal in accordance with the Sherpa Romeo Archiving Policy for Current Signal Transduction Therapy. The table below indicates the level of access a journal has as per Sherpa Romeo's archiving policy.

RoMEO Colour Archiving policy
Green Can archive pre-print and post-print or publisher's version/PDF
Blue Can archive post-print (ie final draft post-refereeing) or publisher's version/PDF
Yellow Can archive pre-print (ie pre-refereeing)
White Archiving not formally supported
FYI:
  1. Pre-prints as being the version of the paper before peer review and
  2. Post-prints as being the version of the paper after peer-review, with revisions having been made.

14. What are the most common citation types In Current Signal Transduction Therapy?

The 5 most common citation types in order of usage for Current Signal Transduction Therapy are:.

S. No. Citation Style Type
1. Author Year
2. Numbered
3. Numbered (Superscripted)
4. Author Year (Cited Pages)
5. Footnote

15. How do I submit my article to the Current Signal Transduction Therapy?

It is possible to find the Word template for any journal on Google. However, why use a template when you can write your entire manuscript on SciSpace , auto format it as per Current Signal Transduction Therapy's guidelines and download the same in Word, PDF and LaTeX formats? Give us a try!.

16. Can I download Current Signal Transduction Therapy in Endnote format?

Yes, SciSpace provides this functionality. After signing up, you would need to import your existing references from Word or Bib file to SciSpace. Then SciSpace would allow you to download your references in Current Signal Transduction Therapy Endnote style according to Elsevier guidelines.

Fast and reliable,
built for complaince.

Instant formatting to 100% publisher guidelines on - SciSpace.

Available only on desktops 🖥

No word template required

Typset automatically formats your research paper to Current Signal Transduction Therapy formatting guidelines and citation style.

Verifed journal formats

One editor, 100K journal formats.
With the largest collection of verified journal formats, what you need is already there.

Trusted by academicians

I spent hours with MS word for reformatting. It was frustrating - plain and simple. With SciSpace, I can draft my manuscripts and once it is finished I can just submit. In case, I have to submit to another journal it is really just a button click instead of an afternoon of reformatting.

Andreas Frutiger
Researcher & Ex MS Word user
Use this template